...
首页> 外文期刊>Vaccine >High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice
【24h】

High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice

机译:巴斯德毕赤酵母中肠道病毒71型重组病毒样颗粒的高产生产及其对小鼠口服病毒攻击的保护作用

获取原文
获取原文并翻译 | 示例

摘要

Enterovirus 71 (EV71) is one of the major causative pathogens of hand, foot and mouth disease (HFMD), which is highly prevalent in the Asia-Pacific regions. Severe HFMD cases with neurological complications and even death are often associated with EV71 infections. However, no licensed EV71 vaccine is currently available. Recombinant virus-like particles (VLPs) of EV71 have been produced and shown to be a promising vaccine candidate in preclinical studies. However, the performance of current recombinant expression systems for EV71 VLP production remains unsatisfactory with regard to VLP yield and manufacturing procedure, and thus hinders further product development. In this study, we evaluated the expression of EV71 VLPs in Pichia pastoris and determined their protective efficacy in mouse models of EV71 infections. We showed that EV71 VLPs could be produced at high levels up to 4.9% of total soluble protein in transgenic P. pastoris yeast co-expressing P1 and 3CD proteins of EV71. The resulting yeast-produced VLPs potently induced neutralizing antibodies against homologous and heterologous EV71 strains in mice. More importantly, maternal immunization with VLPs protected neonatal mice in both intraperitoneal and oral challenge experiments. Collectively, these results demonstrated the success of simple, high-yield production of EV71 VLPs in transgenic P. pastoris, thus lifting the major roadblock in commercial development of VLP-based EV71 vaccines. (C) 2015 Elsevier Ltd. All rights reserved.
机译:肠道病毒71(EV71)是手足口病(HFMD)的主要致病菌之一,在亚太地区非常流行。严重的手足口病并发神经系统并发症甚至死亡通常与EV71感染有关。但是,当前没有获得许可的EV71疫苗。 EV71的重组病毒样颗粒(VLP)已被生产出来,并在临床前研究中证明是有希望的疫苗候选者。但是,当前用于EV71 VLP生产的重组表达系统的性能在VLP产量和制造方法方面仍然不能令人满意,因此阻碍了进一步的产品开发。在这项研究中,我们评估了巴斯德毕赤酵母中EV71 VLP的表达,并确定了它们在EV71感染小鼠模型中的保护作用。我们表明,在共表达EV71的P1和3CD蛋白的转基因巴斯德毕赤酵母中,EV71 VLP可以高水平产生,占总可溶性蛋白的4.9%。所得的酵母产生的VLP有效诱导小鼠中针对同源和异源EV71株的中和抗体。更重要的是,在腹膜内和口服攻毒实验中,用VLP进行母体免疫都能保护新生小鼠。总的来说,这些结果证明了在转基因巴斯德毕赤酵母中简单,高产量地生产EV71 VLP的成功,从而解除了基于VLP的EV71疫苗商业开发的主要障碍。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号